-

Notice Concerning Change of Representative Executive Officer

TOKYO--(BUSINESS WIRE)--H.U. Group Holdings, Inc. (the Company) today announced that it has resolved, at a meeting of the Board of Directors held on January 14, 2026, to change the Company’s Representative Executive Officer as described below.

The Company has recognized that Mr. Goki Ishikawa is the best to lead the execution of MMP as CEO considering he has made significant contributions to the growth of the H.U. Group as an Executive Officer in charge of IVD.

Share

1. Name and job titles of newly appointed Representative Executive Officer

Name

New title

Current title

Goki Ishikawa

Representative Executive Officer,
President and Group CEO

Managing Executive Officer

2. Name and job titles of retiring Representative Executive Officer

Name

New title

Current title

Shigekazu Takeuchi

Director and Executive Officer

Director, Representative Executive Officer, Chairman, President and Group CEO

3. Reason for change

In May 2025, toward realizing its Vision for 2035, the Company announced its Medium-Term Management Plan “H.U. 2030” (MMP) as well as its CEO succession plan including the timing for the selection of the next CEO. As the succession plan progressed, the Company has recognized that Mr. Goki Ishikawa is the best to lead the execution of MMP as CEO considering he has made significant contributions to the growth of the H.U. Group as an Executive Officer in charge of IVD, which led to the resolution.

4. Career summary of newly appointed Representative Executive Officer

Name : Goki Ishikawa
Date of birth : November 18, 1976
Number of shares held : 20,100 shares (As of June 2025)

Career summary :

Mar. 1999

University of Tokyo, B.A. Economics

Apr. 2000

Joined the Japan Defense Agency (currently Ministry of Defense, Japan)

Jun. 2006

Harvard Business School, M.B.A.

Sep. 2006

Joined the Boston Consulting Group

Dec. 2008

Joined Elsevier

Jan. 2012

Joined the Company

Jun. 2013

Director, Fujirebio Diagnostics Inc. (incumbent)

Apr. 2014

Director, FUJIREBIO INC.

Jun. 2014

Director, Fujirebio Europe N.V. (incumbent)

Mar. 2015

Representative Director, FUJIREBIO INC.

Apr. 2016

Representative Managing Director, FUJIREBIO INC.

Apr. 2017

Executive Vice President & Representative Director, FUJIREBIO INC.

Executive Vice President & Representative Director, Fujirebio Holdings, Inc.

Jun. 2018

President & CEO, FUJIREBIO INC.

Jun. 2020

Executive Officer of the Company

President & CEO, Fujirebio Holdings, Inc. (incumbent)

Director, FUJIREBIO INC. (incumbent)

Jun. 2023

Director, SRL, Inc. (incumbent)

Jun. 2025

Managing Executive Officer of the Company (incumbent)

5. Scheduled date of assuming office

April 1st, 2026

Contacts

For media:
Public Relations Section, Public Relations/Sustainability Dept.
Phone: +81-3-6279-0884
Email: pr@hugp.com

For investors and analysts:
IR/SR Dept.
Phone: +81-3-6279-0926
Email: ir@hugp.com

Fujirebio

Details
Headquarters: Tokyo, Japan
CEO: Goki Ishikawa
Employees: 1400
Organization: PRI

Release Versions

Contacts

For media:
Public Relations Section, Public Relations/Sustainability Dept.
Phone: +81-3-6279-0884
Email: pr@hugp.com

For investors and analysts:
IR/SR Dept.
Phone: +81-3-6279-0926
Email: ir@hugp.com

Social Media Profiles
More News From Fujirebio

Fujirebio Acquires Plasma Services Group and Strengthens Its Position as Provider of Critical and High Quality Biological Raw Materials to the IVD and Life Science Industries

MALVERN, Pa. & TOKYO--(BUSINESS WIRE)--H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Diagnostics, Inc., a subsidiary of Fujirebio, has acquired all shares of Plasma Services Group, Inc. (hereinafter “Plasma Services Group”). The transaction value has not been disclosed. Founded in 2004, Plasma Services Group has specialized in the collection, screening and supply of high quality and rare biological ma...

Fujirebio Announces Strategic Collaboration with Stanford Medicine to Advance Infectious Disease Research

TOKYO & SUNNYVALE, Calif.--(BUSINESS WIRE)--Fujirebio, a leading innovator in in-vitro diagnostics, today announced a collaboration with Stanford Medicine (Location: Palo Alto, California, USA) to advance research and innovation in the field of infectious disease testing. This collaboration aims to accelerate the adoption of ultrasensitive immunoassays that incorporate single-molecule counting technology developed by Fujirebio’s Silicon Valley wholly-owned subsidiary, Fluxus, Inc. Greater test...

Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only

GENT, Belgium & MALVERN, Pa. & TOKYO--(BUSINESS WIRE)--H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated LUMIPULSE® G immunoassay analyzers. This CLEIA (chemiluminescent enzyme immunoassay) assay is available for Research Use Only (RUO) and allows for the quantitative measurement of soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) in human cerebrospinal fluid (CSF) and bloo...
Back to Newsroom